SRZNW (Surrozen, Inc. Warrant)
Insider Trading Activity
Every open-market purchase and sale reported by SRZNW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-16 | Charles O Williams | Chief Operating Officer | A | — | — |
| 2026-06-16 | Craig C Parker | Chief Executive Officer | A | — | — |
| 2026-06-16 | Yang Li | Exec. Vice President, Research | A | — | — |
| 2026-06-16 | Andrew Pedrum Maleki | Chief Financial Officer | A | — | — |
| 2026-05-19 | Tim Kutzkey | Director | A | — | — |
| 2026-05-14 | CHRISTOPHER Y CHAI | Director | A | — | — |
| 2026-05-14 | DAVID J WOODHOUSE | Director | A | — | — |
| 2026-05-14 | Anna Berkenblit | Director | A | — | — |
| 2026-05-14 | Mace Rothenberg | Director | A | — | — |
| 2026-05-14 | ERIC BJERKHOLT | Director | A | — | — |
| 2026-05-14 | Mary Haak-Frendscho | Director | A | — | — |
| 2026-05-05 | Charles O Williams | Chief Operating Officer | MIXED | — | — |
| 2026-05-05 | Craig C Parker | Chief Executive Officer | MIXED | — | — |
| 2026-05-05 | Yang Li | Exec. Vice President, Research | MIXED | — | — |
| 2026-04-01 | Yang Li | Exec. Vice President, Research | G | — | — |
| 2026-03-25 | TCG Crossover Fund III, L.P. | 10%+ Owner | Buy | — | — |
| 2026-03-16 | TCG Crossover GP III, LLC | 10%+ Owner | Buy | — | — |
| 2026-02-18 | Yang Li | Exec. Vice President, Research | A | — | — |
| 2026-02-18 | Craig C Parker | Chief Executive Officer | A | — | — |
| 2026-02-18 | Charles O Williams | Chief Operating Officer | A | — | — |
| 2026-02-13 | TCG Crossover Fund III, L.P. | 10%+ Owner | Buy | — | — |
| 2026-02-03 | TCG Crossover Fund III, L.P. | 10%+ Owner | Buy | — | — |
| 2026-01-26 | Charles O Williams | Chief Operating Officer | A | — | — |
| 2026-01-20 | Tim Kutzkey | Director | Buy | — | — |
| 2026-01-20 | Column Group Opportunity III GP, LP | 10%+ Owner | Buy | — | — |
| 2026-01-15 | Tim Kutzkey | Director | Buy | — | — |
| 2026-01-15 | COLUMN GROUP III-A, LP | 10%+ Owner | Buy | — | — |
| 2026-01-08 | TCG Opportunity III GP, LLC | 10%+ Owner | Buy | — | — |
| 2026-01-08 | Tim Kutzkey | Director | Buy | — | — |
| 2026-01-06 | Yang Li | Exec. Vice President, Research | MIXED | — | — |
| 2026-01-06 | Charles O Williams | Chief Operating Officer | MIXED | — | — |
| 2025-12-16 | Craig C Parker | Chief Executive Officer | A | — | — |
| 2025-12-16 | Charles O Williams | Chief Operating Officer | A | — | — |
| 2025-12-16 | Yang Li | Exec. Vice President, Research | A | — | — |
| 2025-12-08 | Tim Kutzkey | Director | Buy | — | — |
| 2025-12-08 | TCG Opportunity III GP, LLC | 10%+ Owner | Buy | — | — |
| 2025-12-02 | Tim Kutzkey | Director | Buy | — | — |
| 2025-11-17 | Column Group Opportunity III, LP | 10%+ Owner | Buy | — | — |
| 2025-11-13 | Andrew Pedrum Maleki | Chief Financial Officer | A | — | — |
| 2025-06-16 | Charles O Williams | CFO and COO | A | — | — |
| 2025-06-16 | Yang Li | Exec. Vice President, Research | A | — | — |
| 2025-06-16 | Craig C Parker | Chief Executive Officer | A | — | — |
| 2025-05-15 | Shao-Lee Lin | Director | A | — | — |
| 2025-05-15 | CHRISTOPHER Y CHAI | Director | A | — | — |
| 2025-05-15 | Anna Berkenblit | Director | A | — | — |
| 2025-05-15 | ERIC BJERKHOLT | Director | A | — | — |
| 2025-05-15 | DAVID J WOODHOUSE | Director | A | — | — |
| 2025-05-15 | Mace Rothenberg | Director | A | — | — |
| 2025-05-15 | Mary Haak-Frendscho | Director | A | — | — |
| 2025-05-05 | Yang Li | Exec. Vice President, Research | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | — | 1,885,000 | — |
| — | — | 1,451,000 | — |
| — | 10%+ Owner | 1,007,090 | — |
| — | 10%+ Owner | 996,502 | — |
| — | 10%+ Owner | 989,893 | — |
| — | 10%+ Owner | 962,718 | — |
| — | Director | 900,292 | — |
| — | 10%+ Owner | 683,225 | — |
| — | 10%+ Owner | 675,610 | — |
| — | 10%+ Owner | 289,549 | — |
| — | Chief Medical Officer | 32,412 | — |
| — | — | 30,000 | — |
| — | — | 30,000 | — |
| — | — | 30,000 | — |
| — | Chief Scientific Officer | 27,216 | — |
| — | Exec. Vice President, Research | 19,233 | — |
| — | Chief Operating Officer | 18,237 | — |
| — | Chief Executive Officer | 18,175 | — |
| — | Chief Financial Officer | 607 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SRZNW quote page; the site-wide leaderboard is on the insider transactions hub.